May 23, 2024, 09:20
Yakup Ergün Summarizes Final Results of RIGHT Choice
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:
“Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC
47.7% patients had investigator-assessed visceral crisis
R+ET vs ChT
mPFS -> 21.8 vs 12.8 mo
ORR -> 66.1% vs 61.8%.”
Proceed to the article.
Source: Yakup Ergün/X
.
aBC
Ankara Numune Training and Research Hospital
cancer
cancer treatment outcomes
chemotherapy
endocrine therapy
HR+/HER2− advanced breast cancer
median progression-free survival
medical oncologist
mPFS
OncoDaily
Oncology
oncology research
ORR
overall response rate
premenopausal women
Research
Ribociclib
RIGHT Choice trial
visceral crisis
Yakup Ergün
Jul 1, 2024, 19:16